

# **Title: Corticosteroid Prescribing Practices at Dermatology Outpatient Departments of Tertiary Care Hospitals: A Multicenter, Cross Sectional Study**

**Nagina Sultana, Jannatul Ferdoush, Wafa Sarwar, Sharif Mohammad Towfiq Hossain, Arifa Hossain, Mosammat Asma.**

**Authors:** 1. Assistant professor, Department of Dermatology, Marine City Medical College, Chittagong.

2. Associate professor, Department of Pharmacology, BGC Trust Medical College, Chittagong.

3. Assistant professor, Institute of health technology, Foujdarhat, Chittagong.

4. Medical Officer, Department of Endocrine and Metabolism

Chattogram Maa-O-Shishu Hospital Medical College, Chattogram

5. Assistant registrar, Department of Dermatology

Chattogram Maa-O-Shishu Hospital Medical College, Chattogram

5. Lecture, Department of pharmacology, BGC Trust Medical College, Chittagong.

Corresponding Author: Nagina Sultana, Assistant professor, Department of dermatology, Marine City Medical College, Chittagong. Email: [nagina.urmi@gmail.com](mailto:nagina.urmi@gmail.com). Contact no: 01781428995.

## **Abstract:**

**Background:** In dermatology, corticosteroids are the most frequently prescribed medication group. The goal of this study was to examine the prescription pattern of glucocorticoids in patients with skin diseases in outpatient dermatology departments (OPD) in tertiary care hospitals.

**Methods:** A prospective, multi-centered, cross-sectional study was undertaken in the dermatology department of government affiliated private medical College hospitals in

Chittagong, Bangladesh, from March 2021 to April 2022. A total of 450 prescriptions from dermatology out-patient department patients with skin diseases were obtained and evaluated for demographics, skin diseases, and corticosteroid use patterns.

**Result:** Out of 450 patients, majority belonged to the age group 21-40 years (44%) and were female (56%). The most frequent indication for prescribing corticosteroids were eczema (20%) urticaria (17%) and allergic Contact dermatitis (7%) and psoriasis (7%). The commonest corticosteroids used were betamethasone (19%) and Clobetasol propionate (17%), Deflazacort (15%). Use of topical steroid combinations with Fusidic acid and Miconazole nitrate were prevalent, (4%) and (5%), respectively. Highly potent steroids were used in 51% cases whereas only 21% were given low potency steroids.

**Conclusion:** Physicians prefer highly potent corticosteroids, according to this study. To improve prescribing, physicians should receive ongoing medical education and be made aware of the irrational use of steroids. Researchers and policymakers can use the baseline data acquired in these studies to enhance judicial prescribing practices. Keywords: Corticosteroids, dermatology, prescribing pattern.

## **Introduction:**

With the advent of topical corticosteroids, the current era of dermatotherapy began, and since then, these agents have been used in a variety of ways, with varying degrees of success. Many people suffer from typical skin disorder that affect people of all ages. Corticosteroids has significant role in the treatment of a various disorders, including skin problems. In topical form, it is likely to have more applications in dermatological therapy. Consultants frequently prescribe these medicines due to their potent immunosuppressive and anti-inflammatory

effects. Interestingly, the similar processes that cause their beneficial anti-inflammatory characteristics are also responsible for their negative effects [1].

Acute urticaria, pemphigus vulgaris, keloid, fixed drug eruptions, eczema, and other dermatological conditions have all been treated with them. As a result, dermatologists have risen to the top of the list of corticosteroid prescribers [2]. However, caution must be taken during the selection process as well as with regard to dose regimes. Corticosteroids are often used to treat psoriasis, as well as adult atopic dermatitis and eczema [3]. Despite their usefulness, their inappropriate and extended use in a variety of dermatological disorders puts a patient at risk for a variety of side effects, ranging from minor to severe [4].

Corticosteroids' most serious side effect is immunosuppression, which might make you more susceptible to bacterial and fungal infections. The side effects of topically administered corticosteroids include adrenal suppression, rosacea induced by steroid, dermal and epidermal thinning, striae, candidiasis (perioral), and hypertrichosis [5]. As a result, doctors should prescribe the lightest corticosteroid feasible to treat dermatological disorders [6].

A correct diagnosis, as well as consideration of the routes of application, frequency of administration, duration of therapy, and adverse effects, are all necessary for successful treatment [7].

Because the medicine is administered directly to the target organ, topical treatments are preferred. The dose can be easily adjusted based on the reaction [8]. Glucocorticoids (topical and systemic) are widely used alone or in combination with other medications [9]. To acquire the best possible benefits at the minimum possible therapeutic dose for the short period at a reasonable cost and with fewer side effects, it is critical to employ the safest and smallest number of steroids feasible [10]. This will allow for more sensible medicine use. Prescribing medications

is a crucial skill that must be examined and provide feedback to physician on a regular basis. Since it indicates a physician's diagnostic ability and attitude toward picking the most appropriate and cost-effective treatment. Their sensible usage, on the other hand, can help to reduce the cutaneous and systemic negative effects that corticosteroids might cause [7]. Physicians should prescribe steroid that will treat the skin related problem with the most therapeutic benefit and the fewest side effects possible [11].

Because of the high disease prevalence and the significant economic burden of skin disease treatment, it is critical to investigate skin disease drug prescribing patterns. Taking these facts into account, current study was conducted to evaluate corticosteroid medication prescribed in dermatology to create baseline data and evaluate various elements of drug prescribing procedures.

## **Materials and Methods:**

A prospective, multicenter, cross-sectional study was done in the Dermatology department of the government affiliated private medical college of Chittagong, Bangladesh from March, 2021 to April, 2022. Data were collected from outpatient department of dermatology of BGC Trust Medical College, Chattogram Maa-O-Shishu Medical College, and Marine City Medical College. The protocol has been approved by the BGC trust medical college's institutional review board.

**Study procedure:** A total of 450 prescriptions of patients with skin problems from the dermatology out-patient department who were on corticosteroids and were correctly selected by the dermatologist of the relevant medical college were obtained and analyzed. A sufficient number of data collectors were engaged to collect the data. The information was gathered

prospectively through direct observation in a specially developed pro forma that included demographic, dermatological disease, and pharmacological information. The prescriptions were examined for the following information: Diagnosed skin diseases, medicine information (corticosteroid alone or in combination with other medicines combination, topical, systemic corticosteroids, and potency).

**Statistical Analysis:** The obtained data was numerically coded and imported into Microsoft Excel 2010, where it was evaluated while keeping respondents' anonymity and privacy in mind. Microsoft Excel was used for statistical analysis, and data was evaluated as frequency and percentages.

## Result:

The study included 450 prescriptions with corticosteroid prescriptions. The majority of the patients (196/450, 44 %) were belongs to 21-40 years age group. Females comprised about 56% of the patients (252/450) (Table I)

Table I: The demographic profile of the participants

Item	No of patients (n=450)	
Age	Frequency	Percentage
<20	88	19%
21-40	196	44%
41-60	105	23%
>60	61	14%
Gender		

Male	198	44%
Female	252	56%

Table II demonstrated that the most prevalent indications for corticosteroid prescription were eczema (20%), urticaria (17%), milia rubra (8%), allergic contact dermatitis (7%), and psoriasis (7%).

Table II: Dermatological conditions indicated for Corticosteroid

Dermatological Indication	Total No of patient (N=450)	
	Frequency	Percentage
Eczema	86	19
Urticaria	77	17
Psoriasis	33	7
Lichen planus	12	3
Allergic Contact dermatitis	31	7
Pemphigus vulgaris	6	1
Adverse drug reaction	22	5
Seborrheic dermatitis	23	5
Keloid	7	2
Alopecia	31	7
Discoid lupus erythematosus	3	1
Planter keratoderma	10	2
Atopic dermatitis	24	5

Plurigo nodularis	11	2
Plurigo simplex	17	4
Miliaria rubra	26	6
Melasma	31	7

Table III demonstrated that the most commonly used corticosteroids were betamethasone (86/450, 19%), clobetasol propionate (77/450, 17%), and deflazacort (67/450, 15%).

Table III: Corticosteroids commonly recommended in dermatological outpatient department.

Corticosteroid	Total N=450	
	Frequency	Percentage
Betamethasone	86	19
Clobetasol propionate	77	17
Deflazacort	67	15
Prednisolone	49	11
Mometasone furoate	33	7
Hydrocortisone	48	11
Flucinolone acetonide	38	8
Triamisolone	34	8
Halobetasol	18	4

Table IV demonstrated that (356/450) 85% corticosteroids were administered alone. The most often used topical steroid combination is with Miconazole Nitrate (23/450, 5%), Fusidic acid (20/450, 4%), Gentamycin (3/450, 1%), and Clotrimazole (21/450, 5%). Over half of the steroids

administered (230/450) were very potent, with just (115/450, 26%) being low potent. In terms of duration of use, 67 % (301/450) of patients had used corticosteroids for more than two weeks. Corticosteroid routes of administration were predominantly topical (67%) and parenteral (7%; 34/450).

Table IV: Detailed corticosteroid prescribed

Corticosteroid	Total No =450 (%)	
	Frequency	Percentage
Corticosteroid used		
Alone	356	85%
Combination	67	15%
Routes of administration		
Topical	300	67%
Oral	116	26%
Per-enteral	34	7%
Topical Corticosteroid in combination with		
Fusidic acid	20	4%
Gentamycin	3	1%
Miconazole nitrate	23	5%
Clotrimazole	21	5%
Corticosteroid Potency		
Very potent	230	51%
Moderately potent	105	23%



Low potent	115	26%
Duration		
≤ 2 weeks	149	33%
>2 weeks	301	67%

**Discussion:** Corticosteroids are among the widely used classes of medicine used in dermatological disease as both short-term and long-term treatments, although they are accompanied with a multitude of side effects [11]. Prescriptions should be audited on a regular basis to improve prescribing quality, decrease side effects and prescribing errors, provide criticism to physicians, and implementation of standard treatment guideline. The study goal was to gather baseline data by assessing corticosteroid prescribing patterns and evaluating monotherapy and the use of co-administered medicines in conjunction with corticosteroids in skin diseases.

The majority (44%) of the patient in this study were between the ages of 21 to 40, 56% were female. This is similar to the study conducted by Bylappa bk et al [12].

According to the current study, eczema (20%), urticaria (17%), miliaria rubra (8%), allergic contact dermatitis (7%), and psoriasis (7%) were the most common reasons for corticosteroid prescription.

Study conducted by Bylappa et al revealed contact dermatitis (47%) and psoriasis (14%) were the common dermatological condition [12]. Similar study conducted by Divyashanthi and Manivannan revealed, [13] psoriasis and contact dermatitis were most common dermatological disorder in which corticosteroid prescribed.

In this study, most common corticosteroids prescribed were betamethasone 19%, Clobetasol propionate 17%, and Deflazacort 15%. Similar findings revealed in Javsén et al study [14]. In contrast, a study by Bylappa et al found clobetasol to be the most widely utilized corticosteroid. Similar to this study, Haiya J S. et al found that fluorinated glucocorticoids Betamethasone and Clobetasol were the most regularly prescribed, whereas non-fluorinated glucocorticoids Prednisolone and Mometasone were the least usually administered [15]. Fluorinated steroids have a higher permeability and produce systemic adverse effects due to their higher lipid solubility. In this study, corticosteroid mainly prescribed alone (85%). Most commonly used topical steroid combination with Fusidic acid 4%, Gentamycin 1%, and Miconazole nitrate 5% and with Clotrimazole 5%. Similarly to the current study, Nerurkar RP et al found that the 88% of prescribed corticosteroids were topical as single drugs, while only 12% were recommended in combinations with other topical medicine such as Salicylic acid, Fusidic acid and Clotrimazole [16]. Various studies conducted in various nations have also found comparable results to the current study [12, 17]. Only if the lesion was limited to a tiny area of skin were topical steroid fixed dose combinations preferred. A short course of an appropriate oral anti-infective was chosen in severe instances [15].

As a result, the topical route was proven to be the most chosen route for medication administration (62 %) in the current investigation. When compared to other studies, one consistent conclusion was that topical formulations were widely utilized in dermatology [10, 18-19]. The principal advantage of adopting the topical route for steroid administration was that it had the fewest side effects, unless systemic injection was required [3, 20]. Unless the disease requires long-term treatment, oral formulations should be administered in a short period with reducing doses [21].

According to the results of the current study, nearly 51% of the steroids administered were very potent, while just 26% were low potent. In terms of duration of use, 67 % had been on corticosteroids for more than two weeks. According to a study by Bhagunde et al, high potency medications were prescribed in 66% of encounters, whereas low/mild potency corticosteroids were prescribed in 11% of encounters [7]. Other studies have shown similar results [15,22]. Long-term and extreme application may result in hypothalamus pituitary adrenal axis suppression as well as local side effects [22,23]. When at all possible, the use of highly potent corticosteroids should be restricted.

Low potency corticosteroids have been considered to be the best for long-term use [24, 25]. High potency corticosteroids have been recommended over low and moderately potent corticosteroids in specific situations, such as atopic dermatitis [26].

This study had few drawbacks. Patients were not followed up on in this cross-sectional trial to assess the efficacy and safety of corticosteroids. Only dermatological out-patient department were included in the study. Inpatients and emergency situations all required to be investigated. Future studies will be able to assess this. Maintaining a balance between judicious use and frequent misuse of corticosteroids, as well as physician attention and patient education during consultation is crucial.

## **Conclusion:**

More emphasis should be placed on rational and comprehensive corticosteroids prescribing for skin diseases. The baseline data generated by these studies can be used by researchers and policymakers to enhance prescribing practices. Continuing medical education is also critical for

professional physicians to put it into action and ensure success. This will help to improve corticosteroid prescribing by providing education during consultations.

## Reference:

1. Bodor N. Design of novel soft corticosteroids. *Curr Probl Dermatol* 1993;21:11–9.
2. Verma SB. Topical corticosteroid misuse in India is harmful and out of control. *BMJ* 2015; 25:351.
3. Giuliana C, Uribe P, Fernández-Peñas P. Rational use of topical corticosteroids. *Aust Prescr* 2013;36:158–61
4. Ankit P, Bharat G. Study of drug utilization pattern of glucocorticosteroid drugs with special emphasis on their immediate adverse effects in a tertiary care teaching rural hospital. *Indian J Pharm Pract* 2010;3(4):18–23.
5. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. *J Am Acad Dermatol* 2006;54(1):1–15.
6. Saravanakumar RT, Prasad GS, Ragul G, Mohanta GP, Manna PK, Moorthi C. Study of prescribing pattern of topical corticosteroids in the department of dermatology of a multispeciality tertiary care teaching hospital in South India. *Int J Res Pharm Sci* 2012;3(4):685–7
7. Bhagunde L, Tamboli SB, Chhabra R. Evaluation of Prescribing Pattern of Corticosteroids in Dermatology OPD in Tertiary Care Hospital. *JMSCR* 2019;7(6):410-419
8. Lee M, Marks R. The role of corticosteroids in dermatology. *Australian Prescriber* 1998;21(1): 9-11.

9. Ramam M, Kumrah L. Systemic Corticosteroid Therapy And The Hypothalamopituitary-Adrenal Axis. Indian Journal of Dermatology 2001;46(01):1-7
10. Sinha A, Kar S, Yadav N, Madke B. Prevalence of topical steroid misuse among rural masses. Indian J Dermatol 2016;61(1)119. DOI: 10.4103/0019-5154.174081 [Crossref]
11. Kumar MA, Noushad PP, Shailaja K, Jayasutha J, Ramasamy C. A study on drug prescribing pattern and use of corticosteroids in dermatological conditions at a tertiary care teaching hospital. International Journal of Pharmaceutical Sciences Review and Research 2011;9:132-5
12. Bylappa BK, Patil RT, Pillai RT. Drug prescribing pattern of topical corticosteroids in dermatology unit of a tertiary-care hospital. Int J Med Sci Public Health 2015;4 . DOI: 10.5455/ijmsph.2015.17052015351
13. Divyashanthi CM, Manivannan E. Prescribing analysis of corticosteroids among the dermatology in-patients in a tertiary care teaching hospital, Karaikal, Puducherry: a prospective observational study. Int J Pharm Biol Sci 2014;5(2):324–30
14. Javsén C, Suman RK, Patil VG, Deshmukh YA. To study prescription pattern of corticosteroids in skin OPD in tertiary care teaching hospital. Asian J Pharmacol Toxicol 2014;2(4):23–6
15. Sheth HJ, Chaudhary RG, Malhotra SD. Evaluation of corticosteroid use in outpatient department of dermatology of a tertiary care teaching hospital: a prospective observational study. Int J Med Res Rev. 2019;7(3):243-252.

16. Nerukar RP, Kokane MR, Mehta MN. Study of prescribing pattern of topical corticosteroids in dermatology outpatient department in a tertiary care hospital in India. *Int J Basic Clin Pharmacol*. 2016;5(5):2194-2198. DOI: 10.18203/2319-2003.ijbcp20163261 [Crossref]
17. Mirshad PV, Afzal Khan AK, Rahiman FOM, Muneersha MTK. Prescription audit of corticosteroid usage in the department of dermatology at a tertiary care teaching hospital. *Int J Basic Clin Pharmacol* 2013;2(4):411–3.
18. Arellano FM, Wentworth CE, Arana A, Fernández C, Carle PF. Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic Dermatitis. *Journal of Investigative dermatology* 2007;127:808-16.
19. Schaefer ET, Fitzgerald JF, Molleston JP, Croffie JM, Pfefferkorn MD, Corkins MR, et al. Comparison of Oral Prednisone and Topical Fluticasone in the Treatment of Eosinophilic Esophagitis: A Randomized Trial in Children. *Clinical Gastroenterology and Hepatology* 2008;6:2165-73.
20. Bewley A and Dermatology Working Group. Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids. *British Journal of Dermatology* 2008;158:917-20.
21. Sarkar C, Das B, Sripathi H. Drug prescribing pattern in dermatology in a teaching hospital in western Nepal. *JNMA* 2001;41:241-6
22. Bijoy KP, Vidyadhar RS, Palak P, Chintan SP, Atmaram PP. Drug prescribing and economic analysis for skin diseases in dermatology OPD of an Indian tertiary care teaching hospital: a periodic audit. *Indian J Pharm Pract* 2012;5(1):28–33.

23. Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus pituitary- adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol. 1993;29:501-3.
24. Horn EJ, Domm S, Katz HI, Lebwohl M, Mrowietz U, and Kragballe K. Topical corticosteroids in psoriasis: strategies for improving safety. Journal of the European Academy of Dermatology and Venereology 2010;24:119-24.
25. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. Journal der Deutschen Dermatologischen Gesellschaft 2007;5:1-119.
26. Eskil J. Nilsson, Claes G. Henning, Jelena Magnusson. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. Journal of the American Academy of Dermatology 1992;27:29-34.